JP2019514854A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514854A5 JP2019514854A5 JP2018550790A JP2018550790A JP2019514854A5 JP 2019514854 A5 JP2019514854 A5 JP 2019514854A5 JP 2018550790 A JP2018550790 A JP 2018550790A JP 2018550790 A JP2018550790 A JP 2018550790A JP 2019514854 A5 JP2019514854 A5 JP 2019514854A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inhibitor
- hydroxy
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 88
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 48
- 239000012664 BCL-2-inhibitor Substances 0.000 claims description 36
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims description 36
- 125000001475 halogen functional group Chemical group 0.000 claims description 36
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 32
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 32
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 30
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 30
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 30
- 239000003207 proteasome inhibitor Substances 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 16
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 16
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 15
- -1 2-chloro-4-trifluoromethylphenyl Chemical group 0.000 claims description 13
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 12
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 12
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 12
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229950002736 marizomib Drugs 0.000 claims description 12
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 claims description 12
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 claims description 12
- 229960003648 ixazomib Drugs 0.000 claims description 10
- MXAYKZJJDUDWDS-LBPRGKRZSA-N ixazomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl MXAYKZJJDUDWDS-LBPRGKRZSA-N 0.000 claims description 10
- 229960001183 venetoclax Drugs 0.000 claims description 10
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims description 10
- 229960001467 bortezomib Drugs 0.000 claims description 8
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 8
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims description 8
- 230000002489 hematologic effect Effects 0.000 claims description 8
- QYPJBTMRYKRTFG-UHFFFAOYSA-N (-)-marinopyrrole A Chemical compound OC1=CC=CC=C1C(=O)C1=C(N2C(=CC(Cl)=C2Cl)C(=O)C=2C(=CC=CC=2)O)C(Cl)=C(Cl)N1 QYPJBTMRYKRTFG-UHFFFAOYSA-N 0.000 claims description 6
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 229960002438 carfilzomib Drugs 0.000 claims description 6
- 108010021331 carfilzomib Proteins 0.000 claims description 6
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 229950004847 navitoclax Drugs 0.000 claims description 6
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 claims description 5
- 201000005787 hematologic cancer Diseases 0.000 claims description 5
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 5
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 4
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 claims description 4
- KUUJEXLRLIPQQJ-HNNXBMFYSA-N (2s)-1-(3,6-dibromocarbazol-9-yl)-3-piperazin-1-ylpropan-2-ol Chemical compound C([C@H](O)CN1C2=CC=C(Br)C=C2C2=CC(Br)=CC=C21)N1CCNCC1 KUUJEXLRLIPQQJ-HNNXBMFYSA-N 0.000 claims description 4
- CIJUJPVFECBUKG-BDQAORGHSA-N (2s)-2-(3-aminopropyl)-5-(2,5-difluorophenyl)-n-methoxy-n-methyl-2-phenyl-1,3,4-thiadiazole-3-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1([C@]2(CCCN)SC(=NN2C(=O)N(C)OC)C=2C(=CC=C(F)C=2)F)=CC=CC=C1 CIJUJPVFECBUKG-BDQAORGHSA-N 0.000 claims description 4
- NHMUTADCTDDWPV-YFNVTMOMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-4-methylpentanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHMUTADCTDDWPV-YFNVTMOMSA-N 0.000 claims description 4
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 claims description 4
- WUGANDSUVKXMEC-UHFFFAOYSA-N 2-[4-[(4-bromophenyl)sulfonylamino]-1-hydroxynaphthalen-2-yl]sulfanylacetic acid Chemical compound C=12C=CC=CC2=C(O)C(SCC(=O)O)=CC=1NS(=O)(=O)C1=CC=C(Br)C=C1 WUGANDSUVKXMEC-UHFFFAOYSA-N 0.000 claims description 4
- SOYCFODXNRVBTI-UHFFFAOYSA-N 2-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-1h-isoquinolin-2-yl]-5-[3-[4-[3-(dimethylamino)prop-1-ynyl]-2-fluorophenoxy]propyl]-1,3-thiazole-4-carboxylic acid Chemical compound FC1=CC(C#CCN(C)C)=CC=C1OCCCC1=C(C(O)=O)N=C(N2CC3=C(C(=O)NC=4SC5=CC=CC=C5N=4)C=CC=C3CC2)S1 SOYCFODXNRVBTI-UHFFFAOYSA-N 0.000 claims description 4
- JWCVUOLQOHIRML-UHFFFAOYSA-N 3,6-dibromo-9-(2-fluoro-3-piperazin-1-ylpropyl)carbazole;dihydrochloride Chemical compound Cl.Cl.C12=CC=C(Br)C=C2C2=CC(Br)=CC=C2N1CC(F)CN1CCNCC1 JWCVUOLQOHIRML-UHFFFAOYSA-N 0.000 claims description 4
- WRLVHADVOGFZOZ-UHFFFAOYSA-N 4-[(2-ethoxyphenyl)diazenyl]-5-methyl-2-(4-phenyl-1,3-thiazol-2-yl)-1H-pyrazol-3-one Chemical compound CCOC1=CC=CC=C1N=NC2=C(NN(C2=O)C3=NC(=CS3)C4=CC=CC=C4)C WRLVHADVOGFZOZ-UHFFFAOYSA-N 0.000 claims description 4
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims description 4
- 101100325758 Arabidopsis thaliana BAM7 gene Proteins 0.000 claims description 4
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- 206010007953 Central nervous system lymphoma Diseases 0.000 claims description 4
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 4
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 4
- 101150054675 MIM1 gene Proteins 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 4
- PQAPVTKIEGUPRN-UHFFFAOYSA-N N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide Chemical compound CC(C)C1=CC=CC=C1CC1=CC(C(=O)NC=2C=CC(=CC=2)S(=O)(=O)C=2C(=CC=CC=2)C(C)(C)C)=C(O)C(O)=C1O PQAPVTKIEGUPRN-UHFFFAOYSA-N 0.000 claims description 4
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims description 4
- 108010064641 ONX 0912 Proteins 0.000 claims description 4
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 229960002563 disulfiram Drugs 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims description 4
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 4
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 4
- 229960004584 methylprednisolone Drugs 0.000 claims description 4
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 claims description 4
- 229950006584 obatoclax Drugs 0.000 claims description 4
- 229950005750 oprozomib Drugs 0.000 claims description 4
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 4
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 claims description 4
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 4
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 4
- XMVAWGSQPHFXKU-UHFFFAOYSA-N 7-[5-[[4-[4-(dimethylsulfamoyl)piperazin-1-yl]phenoxy]methyl]-1,3-dimethylpyrazol-4-yl]-1-(2-morpholin-4-ylethyl)-3-(3-naphthalen-1-yloxypropyl)indole-2-carboxylic acid Chemical compound C1CN(S(=O)(=O)N(C)C)CCN1C(C=C1)=CC=C1OCC1=C(C=2C=3N(CCN4CCOCC4)C(C(O)=O)=C(CCCOC=4C5=CC=CC=C5C=CC=4)C=3C=CC=2)C(C)=NN1C XMVAWGSQPHFXKU-UHFFFAOYSA-N 0.000 claims description 3
- SJFBTAPEPRWNKH-CCKFTAQKSA-N delanzomib Chemical compound CC(C)C[C@@H](B(O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(C=2C=CC=CC=2)=N1 SJFBTAPEPRWNKH-CCKFTAQKSA-N 0.000 claims description 3
- 108700002672 epoxomicin Proteins 0.000 claims description 3
- DOGIDQKFVLKMLQ-JTHVHQAWSA-N epoxomicin Chemical compound CC[C@H](C)[C@H](N(C)C(C)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 DOGIDQKFVLKMLQ-JTHVHQAWSA-N 0.000 claims description 3
- GEZHEQNLKAOMCA-RRZNCOCZSA-N (-)-gambogic acid Chemical compound C([C@@H]1[C@]2([C@@](C3=O)(C\C=C(\C)C(O)=O)OC1(C)C)O1)[C@H]3C=C2C(=O)C2=C1C(CC=C(C)C)=C1O[C@@](CCC=C(C)C)(C)C=CC1=C2O GEZHEQNLKAOMCA-RRZNCOCZSA-N 0.000 claims description 2
- RAYNZUHYMMLQQA-ZEQRLZLVSA-N 2,3,5-trihydroxy-7-methyl-n-[(2r)-2-phenylpropyl]-6-[1,6,7-trihydroxy-3-methyl-5-[[(2r)-2-phenylpropyl]carbamoyl]naphthalen-2-yl]naphthalene-1-carboxamide Chemical compound C1([C@@H](C)CNC(=O)C=2C3=CC(C)=C(C(=C3C=C(O)C=2O)O)C=2C(O)=C3C=C(O)C(O)=C(C3=CC=2C)C(=O)NC[C@H](C)C=2C=CC=CC=2)=CC=CC=C1 RAYNZUHYMMLQQA-ZEQRLZLVSA-N 0.000 claims description 2
- GAQGZEPUTWPXOG-UHFFFAOYSA-N 2-[[6-amino-2-[[4-methyl-2-[[4-methylsulfanyl-2-(pyrrolidine-2-carbonylamino)butanoyl]amino]pentanoyl]amino]hexanoyl]amino]pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)NC(=O)C(CCCCN)NC(=O)C(CC(C)C)NC(=O)C(CCSC)NC(=O)C1CCCN1 GAQGZEPUTWPXOG-UHFFFAOYSA-N 0.000 claims description 2
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 claims description 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 claims description 2
- 102000055102 bcl-2-Associated X Human genes 0.000 claims description 2
- GEZHEQNLKAOMCA-UHFFFAOYSA-N epiisogambogic acid Natural products O1C2(C(C3=O)(CC=C(C)C(O)=O)OC4(C)C)C4CC3C=C2C(=O)C2=C1C(CC=C(C)C)=C1OC(CCC=C(C)C)(C)C=CC1=C2O GEZHEQNLKAOMCA-UHFFFAOYSA-N 0.000 claims description 2
- GEZHEQNLKAOMCA-GXSDCXQCSA-N gambogic acid Natural products C([C@@H]1[C@]2([C@@](C3=O)(C\C=C(/C)C(O)=O)OC1(C)C)O1)[C@H]3C=C2C(=O)C2=C1C(CC=C(C)C)=C1O[C@@](CCC=C(C)C)(C)C=CC1=C2O GEZHEQNLKAOMCA-GXSDCXQCSA-N 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- QALPNMQDVCOSMJ-UHFFFAOYSA-N isogambogic acid Natural products CC(=CCc1c2OC(C)(CC=C(C)C)C=Cc2c(O)c3C(=O)C4=CC5CC6C(C)(C)OC(CC=C(C)/C(=O)O)(C5=O)C46Oc13)C QALPNMQDVCOSMJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 201000003791 MALT lymphoma Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 51
- 0 *C1N(*)CCC1c1c(*)cc(*)c2c1OC(*)=CC2=O Chemical compound *C1N(*)CCC1c1c(*)cc(*)c2c1OC(*)=CC2=O 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- MRPGRAKIAJJGMM-OCCSQVGLSA-N CN(CC1)[C@@H](CO)[C@@H]1c(c(OC(c(ccc(C(F)(F)F)c1)c1Cl)=C1)c(c(O)c2)C1=O)c2O Chemical compound CN(CC1)[C@@H](CO)[C@@H]1c(c(OC(c(ccc(C(F)(F)F)c1)c1Cl)=C1)c(c(O)c2)C1=O)c2O MRPGRAKIAJJGMM-OCCSQVGLSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022119166A JP7416872B2 (ja) | 2016-03-28 | 2022-07-27 | 癌の治療のための配合剤 |
| JP2023223257A JP2024038227A (ja) | 2016-03-28 | 2023-12-28 | 癌の治療のための配合剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314356P | 2016-03-28 | 2016-03-28 | |
| US62/314,356 | 2016-03-28 | ||
| PCT/US2017/024618 WO2017172826A1 (en) | 2016-03-28 | 2017-03-28 | Pharmaceutical combinations for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119166A Division JP7416872B2 (ja) | 2016-03-28 | 2022-07-27 | 癌の治療のための配合剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514854A JP2019514854A (ja) | 2019-06-06 |
| JP2019514854A5 true JP2019514854A5 (enExample) | 2020-05-07 |
| JP7114478B2 JP7114478B2 (ja) | 2022-08-08 |
Family
ID=59966407
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550790A Active JP7114478B2 (ja) | 2016-03-28 | 2017-03-28 | 癌の治療のための配合剤 |
| JP2022119166A Active JP7416872B2 (ja) | 2016-03-28 | 2022-07-27 | 癌の治療のための配合剤 |
| JP2023223257A Pending JP2024038227A (ja) | 2016-03-28 | 2023-12-28 | 癌の治療のための配合剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022119166A Active JP7416872B2 (ja) | 2016-03-28 | 2022-07-27 | 癌の治療のための配合剤 |
| JP2023223257A Pending JP2024038227A (ja) | 2016-03-28 | 2023-12-28 | 癌の治療のための配合剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US11135198B2 (enExample) |
| EP (1) | EP3436002B1 (enExample) |
| JP (3) | JP7114478B2 (enExample) |
| KR (5) | KR102494039B1 (enExample) |
| CN (1) | CN109689047B (enExample) |
| AU (4) | AU2017241914B2 (enExample) |
| CA (2) | CA3018932C (enExample) |
| IL (3) | IL295472B2 (enExample) |
| MX (3) | MX2018011666A (enExample) |
| NZ (2) | NZ747404A (enExample) |
| RU (1) | RU2726367C2 (enExample) |
| WO (1) | WO2017172826A1 (enExample) |
| ZA (2) | ZA201806819B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2624981T3 (es) | 2011-07-01 | 2017-07-18 | Dana-Farber Cancer Institute, Inc. | Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario |
| AU2014361798B2 (en) | 2013-12-13 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| KR102494039B1 (ko) * | 2016-03-28 | 2023-01-30 | 프레시지 바이오싸이언시스, 인크. | 암 치료를 위한 제약학적 조합물 |
| WO2019089641A1 (en) * | 2017-10-31 | 2019-05-09 | Eisai R&D Management Co., Ltd. | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use |
| CN108186642B (zh) * | 2018-01-11 | 2019-11-08 | 广西师范大学 | 一种协同起作用治疗肺癌的药物组合物 |
| CN108261414B (zh) * | 2018-01-11 | 2019-09-06 | 广西师范大学 | 一种治疗肺癌的药物组合物 |
| JP2021534114A (ja) * | 2018-08-14 | 2021-12-09 | エムイーアイ ファーマ，インク． | 併用療法 |
| WO2020092615A1 (en) * | 2018-11-01 | 2020-05-07 | Oregon Health & Science University | Treatments for venetoclax-resistant and venetoclax-sensitive acute myeloid leukemia |
| EP3952861A4 (en) | 2019-04-11 | 2023-01-11 | MEI Pharma, Inc. | VORUCICLIB POLYMORPHS AND PROCESSES FOR THEIR PRODUCTION AND USE |
| EP4041239B1 (en) * | 2019-10-08 | 2025-09-03 | Dana-Farber Cancer Institute, Inc. | A pyrrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases |
| CN115666574A (zh) * | 2020-05-07 | 2023-01-31 | 里科瑞尔姆Ip控股有限责任公司 | 组合 |
| CN117043159A (zh) * | 2020-11-19 | 2023-11-10 | 梅制药公司 | Kras突变型癌症的治疗 |
| JP2024500288A (ja) * | 2020-11-19 | 2024-01-09 | メイ ファーマ，インク． | Ｋｒａｓ変異癌の治療 |
| CN113018357A (zh) * | 2021-02-08 | 2021-06-25 | 湖南农业大学 | 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途 |
| WO2022217133A1 (en) * | 2021-04-10 | 2022-10-13 | Mei Pharma, Inc. | Voruciclib dosing regimens and methods of treatment including the same |
| WO2024239512A1 (zh) * | 2023-05-22 | 2024-11-28 | 劲方医药科技(上海)有限公司 | 药物组合及其在治疗癌症中的用途 |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2219867A1 (en) * | 1997-10-31 | 1999-04-30 | Jiangping Wu | The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock |
| AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US7271193B2 (en) | 2002-07-08 | 2007-09-18 | Nicholas Piramal India, Ltd. | Inhibitors of cyclin-dependent kinases and their use |
| TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7642260B2 (en) | 2003-11-13 | 2010-01-05 | Abbott Laboratories, Inc. | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| CN101006065B (zh) | 2004-06-17 | 2012-07-11 | 英菲尼蒂发现公司 | 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法 |
| US7842815B2 (en) | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| TWI337608B (en) | 2005-05-12 | 2011-02-21 | Abbott Lab | Apoptosis promoters |
| EP1888543B1 (en) | 2005-05-24 | 2012-08-01 | Abbott Laboratories | Apoptosis promoters |
| US20090142337A1 (en) * | 2006-05-08 | 2009-06-04 | Astex Therapeutics Limited | Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment |
| EP2046738B1 (en) | 2006-06-21 | 2014-06-11 | Piramal Enterprises Limited | Enantiomerically pure flavone derivatives for the treatment of proliferative disorders and processes for their preparation |
| US8822526B2 (en) * | 2007-05-15 | 2014-09-02 | Piramal Enterprises Limited | Synergistic pharmaceutical combination for the treatment of cancer |
| US9259399B2 (en) * | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| CN102325531B (zh) | 2008-12-19 | 2014-04-02 | 健泰科生物技术公司 | 化合物和使用方法 |
| TWI535712B (zh) | 2010-08-06 | 2016-06-01 | 阿斯特捷利康公司 | 化合物 |
| MX2013005661A (es) * | 2010-11-19 | 2013-09-13 | Piramal Entpr Ltd | Combinacion farmaceutica de paclitaxel y un inhibidor cdk (quinasa dependiente de ciclina). |
| TW201300105A (zh) * | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
| WO2014018668A2 (en) * | 2012-07-24 | 2014-01-30 | Genoa Pharmaceuticals, Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US9241941B2 (en) * | 2012-09-20 | 2016-01-26 | Memorial Sloan-Kettering Cancer Center | Methods for treatment of lymphomas with mutations in cell cycle genes |
| JP6347793B2 (ja) | 2013-01-16 | 2018-06-27 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法 |
| KR20150131276A (ko) * | 2013-03-14 | 2015-11-24 | 오닉스 세라퓨틱스, 인크. | 디펩타이드 및 트리펩타이드 에폭시 케톤 프로테이스 억제제 |
| AU2014296032A1 (en) * | 2013-07-31 | 2016-03-17 | Windward Pharma, Inc. | Aerosol tyrosine kinase inhibitor compounds and uses thereof |
| US10314842B2 (en) | 2013-12-02 | 2019-06-11 | Cornell University | Methods for treating B cell proliferative disorders |
| ES2818110T3 (es) * | 2014-02-28 | 2021-04-09 | Merck Sharp & Dohme | Tratamiento del cáncer con una combinación que comprende dinaciclib |
| WO2015181737A1 (en) * | 2014-05-28 | 2015-12-03 | Piramal Enterprises Limited | Pharmaceutical combination for the treatment of cancer |
| US20170231986A1 (en) | 2014-08-11 | 2017-08-17 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor |
| US9637488B2 (en) * | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| KR102494039B1 (ko) * | 2016-03-28 | 2023-01-30 | 프레시지 바이오싸이언시스, 인크. | 암 치료를 위한 제약학적 조합물 |
-
2017
- 2017-03-28 KR KR1020217021031A patent/KR102494039B1/ko active Active
- 2017-03-28 RU RU2018137687A patent/RU2726367C2/ru active
- 2017-03-28 EP EP17776498.2A patent/EP3436002B1/en active Active
- 2017-03-28 IL IL295472A patent/IL295472B2/en unknown
- 2017-03-28 AU AU2017241914A patent/AU2017241914B2/en active Active
- 2017-03-28 KR KR1020237037917A patent/KR20230156443A/ko active Pending
- 2017-03-28 NZ NZ747404A patent/NZ747404A/en unknown
- 2017-03-28 KR KR1020237019958A patent/KR102599512B1/ko active Active
- 2017-03-28 KR KR1020237002852A patent/KR102545392B1/ko active Active
- 2017-03-28 CA CA3018932A patent/CA3018932C/en active Active
- 2017-03-28 NZ NZ757763A patent/NZ757763A/en unknown
- 2017-03-28 IL IL312398A patent/IL312398A/en unknown
- 2017-03-28 CA CA3103604A patent/CA3103604C/en active Active
- 2017-03-28 JP JP2018550790A patent/JP7114478B2/ja active Active
- 2017-03-28 KR KR1020187030575A patent/KR102275758B1/ko active Active
- 2017-03-28 MX MX2018011666A patent/MX2018011666A/es unknown
- 2017-03-28 WO PCT/US2017/024618 patent/WO2017172826A1/en not_active Ceased
- 2017-03-28 CN CN201780032783.3A patent/CN109689047B/zh active Active
- 2017-03-28 US US16/089,276 patent/US11135198B2/en active Active
-
2018
- 2018-09-17 IL IL261824A patent/IL261824B2/en unknown
- 2018-09-25 MX MX2022011750A patent/MX2022011750A/es unknown
- 2018-09-25 MX MX2022002318A patent/MX2022002318A/es unknown
- 2018-10-12 ZA ZA2018/06819A patent/ZA201806819B/en unknown
-
2019
- 2019-05-28 US US16/423,216 patent/US20190275004A1/en not_active Abandoned
-
2020
- 2020-02-20 AU AU2020201247A patent/AU2020201247B2/en active Active
-
2021
- 2021-06-03 US US17/337,952 patent/US12171744B2/en active Active
- 2021-07-09 US US17/371,774 patent/US12121508B2/en active Active
- 2021-10-08 ZA ZA2021/07579A patent/ZA202107579B/en unknown
- 2021-11-23 AU AU2021273532A patent/AU2021273532B2/en active Active
-
2022
- 2022-07-27 JP JP2022119166A patent/JP7416872B2/ja active Active
-
2023
- 2023-12-28 JP JP2023223257A patent/JP2024038227A/ja active Pending
-
2024
- 2024-01-11 AU AU2024200194A patent/AU2024200194A1/en active Pending
- 2024-10-21 US US18/921,886 patent/US20250221961A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514854A5 (enExample) | ||
| JP2022141916A5 (enExample) | ||
| RU2018137687A (ru) | Фармацевтические комбинации для лечения злокачественной опухоли | |
| US20220280495A1 (en) | Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers | |
| JP2019521988A5 (enExample) | ||
| JP2018524298A5 (enExample) | ||
| US11382905B2 (en) | Immunomodulation by IAP inhibitors | |
| RU2762193C2 (ru) | Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени | |
| JP2020172502A5 (enExample) | ||
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| JP2009504763A5 (enExample) | ||
| RU2009114159A (ru) | N-метиламинометилизоидольные соединения, композиции, включающие их, и способы их применения | |
| RU2007132181A (ru) | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ | |
| JP2018524347A5 (enExample) | ||
| RU2003132687A (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
| JP2016521280A5 (enExample) | ||
| RU2019138222A (ru) | Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли | |
| JP2017530983A5 (enExample) | ||
| JP2015524472A5 (enExample) | ||
| EP3490553B1 (en) | Combination comprising an indolinone compound and its use in the treatment of lymphoma | |
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| RU2020121162A (ru) | Противоопухолевый агент | |
| JP2009543874A5 (enExample) | ||
| RU2006138035A (ru) | Применение производного фенотиазина для профилактики и/или лечения потери слуха | |
| EA200600377A1 (ru) | Новая композиция |